Boston, Sept. 5, 2014, — The annual meeting of Sino-American Pharmaceutical Professionals Association (SAPA) will be held a week from today at Princeton University. The online registration will be close at 9:00 PM on Sept. 10. The conference features leading scientists and executives from the pharma industry from both the US and China.
The online registration will be close at 9:00 PM on Sept. 10. The onsite registration will be $10 for the conference and $25 for the evening dinner. Online registration will also receive one year free SAPA membership.
Conference Schedule>
8:45 – 9:00 am Opening Remarks
Weiguo Dai, PhD, SAPA President
SAPA President Dr. Weiguo Dai speaks at a SAPA conference at Villanova University(file photo).
Session Moderators: Xiaole Shen, PhD, John Sun, PhD, and Frank Gan, PharmD
9:00 – 9:30 am Improving the Lives of Patients Worldwide by Delivering Truly Innovative Medicine
Jerome B. Zeldis, MD, PhD, CMO, Celgene Corp; CEO, Celgene Global Health
Celgene’s discovery and development platforms for drug and cell-based therapies allow them to both create and retain significant value within the therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind their success, enabling target- to-therapeutic platforms that integrate both small-molecule and cell-based therapies.
9:30 – 10:00 am Deliver Breakthrough Medicine for Patients with Reduced Ejection Fraction Chronic Heart Failure
Patrice Matchaba, MD, Executive VP, Global Head, Cardio-Metabolic Development Franchise, Novartis Pharmaceuticals Corporation
ENTRESTO (formerly LCZ696) is an exemplary achievement as the result of collective passion and significant efforts from the Novartis Global Pharma team over the past two decades. Recently FDA approved the product for patients with Reduced Ejection Fraction Chronic Heart Failure. This truly innovative medicine offers new hope for millions of patients worldwide, significantly reducing their risk of going into the hospital and ultimately, dying. Dr. Matchaba will share with the audience on the amazing and memorable journey to discover and develop this innovative medicine. The moment like this reminds us all on why we are in the healthcare business to serve patients globally.
10:00 – 10:30 am Searching for the Molecular Basis of Major Depressive Disorder (MDD)
Paul Greengard, PhD, Vincent Astor Professor, Rockefeller University, 2000 Nobel Prize in Physiology or Medicine
A protein called p11 (S100A10, a member of the S100 family of proteins) plays a central role in the regulation of mood and in the response to antidepressant agents. Constitutive p11 knockout mice manifest a depressive phenotype and exhibit a loss of neurogenic response and behavioral response to antidepressant agents. The depressive phenotype seen in the constitutive p11 knockout mice is attributable to giant cholinergic interneurons in the nucleus accumbens. The loss of behavioral response to antidepressants can be mimicked by deletion of p11 from any of several brain regions. The antidepressant action of p11 and its binding partner, annexin A2, requires the binding of the (p11)2 (annexinA2)2- heterotetramer to a chromatin-remodeling factor, SMARCA3. SMARCA3, in turn, regulates some of the neurogenic and behavioral actions of the antidepressants.
10:30 – 10:45 am Coffee Break
Session Moderators: Weiguo Dai, PhD, Veronica Chen, PhD, and Lei Tang, PhD 10:45 – 10:50 am Plenary Remarks
Dongbai Ye, Counselor Consul, Consulate General of the People’s Republic of China in New York
10:50 – 11:20 am Creating Value through Innovation
Thad Huston, Group CFO, Medical Devices, Johnson & Jonson, Former President, Xian Janssen Pharmaceuticals
Johnson & Johnson is a broadly based global healthcare company with expertise in all stages of research and development of large and small molecule therapeutics, vaccines, medical devices, and diagnostics and consumer products. Johnson and Johnson has driven vigorously innovation and fostered partnership to develop and/or find the best science and technology to solve the greatest unmet needs of our time. As the former President of Xian Janssen Pharmaceuticals, the speaker will share his experience on how to lead innovation and collaboration in the dynamic pharmaceutical industry in China. Also the presentation will present Johnson and Johnson’s strategy and approach in expanding the market leadership with innovative products and customer-focused solutions. Additionally China market represents a source for significant long-term growth and Johnson and Johnson has expanded its organization significantly to bring high quality and affordable medicines to the patients in China. The speaker will share his insight on the critical leadership attributes required for emerging industry leaders in China.
11:20 – 11:50 am Life Science Opportunity in China
Wei (William) Cao, PhD, CEO, Cellular Biomedicine Group, Inc.
On the way to become the world largest medical market, China has shown her ambition to be a significant player in healthcare industry. China presents herself as an attractive place for Western educated “sea turtles” (returnees) to exercise
their entrepreneurship desire, while US remain the primary birthplace of biotech leaders. Team, fund raising environment, regulatory hurdles, intricate business practice, and long distance family life are considered as the main challenges to returnee entrepreneurs. Idea and platform, sound business model, team and perseverance are the keys to success.
11:50 – 12:20 pm Harnessing the Immune System to Treat Cancer
Rachel W. Humphrey, MD, VP, Immuno-Oncology, Eli Lilly and Company
The US and European approval of ipilimumab for the treatment of advanced melanoma in 2011 signaled the beginning of a paradigm shift in cancer therapy. The PD(L)-1 inhibitors appear to be more active and safer than ipilimumab in melanoma and provide additional reasons to be enthusiastic about immunotherapy. However, while immunotherapies are active in a wide array of cancers, the majority of cancer patients do not respond and the medical need remains high. Improved efficacy through the combination of CTLA-4 and PD(L)-1 inhibitors are achieved at a meaningful cost to safety and, to date, meaningful incremental improvement in risk:benefit remains elusive. This talk will focus on recent scientific observations and their potential impact on the path forward in immunotherapy.
12:20 – 12:30 pm SAPA Annual Election Results and SAPA Scholarship Announcement
12:30 – 1:30 pm Lunch (Sponsored by WuXi AppTec, Complimentary to all registered attendees and speakers)
Parallel Session II: New Era of Breakthrough Science and Innovative R&D
Session Moderators: Jian Liu, PhD, Cai Li, PhD, and Wei Ding, PhD
3:30 – 3:50 pm “Contributing to Society through Science and Technology” – Innovation & Perspectives from a Global Instrument Company
Terry Adams, VP of Marketing, Shimadzu
Since 1875 Shimadzu has fulfilled our corporate motto “Contributing to Society and Technology “by creating measurement tools for scientists, engineers, clinicians and educators. Now as we are beginning to see emergence as a true Global Company, Shimadzu has been strategically planning for the future. No doubt the world is changing, science is improving lives at a pace no one could imagine, and the amount of quality measurement data need to drive such changes is overwhelming. We need to consider what it means to be truly ‘Global’ and what is the responsible role of our company. To embrace those challenges, we have been investing more efforts on global manufacturing, collaborative research projects and have constructed ‘Solution Centers’ around the world. The latest step in this direction is creation of ‘Innovation Centers’ in various geographical regions and for this talk examples from both China and USA will be discussed.
3:50 – 4:10 pm Fosun Pharma: Dream and Journey 复星医药：故事与梦想
Ying Shao, VP, Fosun Pharmaceuticals
复星医药成立于 1994 年，1998 年 8 月和 2012 年 10 月分别在上海证券交易所和香港联合 交易所主板挂牌上市（股票代码：600196-SH，02196-HK），是中国医药行业中处于领先 地位的上市公司。
复星医药的发展愿景：成为全球主流市场的一流企业，医药健康领域最受尊敬的企业公民之 一。
复星医药秉承“关爱生命，不断创新，精益求精，合作共赢”的价值观，以“中国动力嫁接全球 资源”，专注现代生物医药健康产业，在制药、医药商业与消费品、医疗服务和医疗器械、 医学诊断等方面均取得了突出业绩。
复星医药始终将自主创新作为企业发展的源动力，通过持续的高投入，在上海、重庆、美国 旧金山三地建立了高效的国际化研发团队，构建了较为完善的研发体系，在小分子化学创新 药、生物类似药、高价值仿制药、特色给药技术等领域打造了高效的研发平台。公司通过自 建，参股、控股、并购有竞争力的国内外研发型公司，全面融入全球研发生态圈和价值链， 以锻造公司的核心竞争力。
复星医药诚邀有创业梦和发展梦的优秀团队和科学家加盟，共同实践并见证中国制药企业成 为世界品牌的发展历程。
4:10 – 4:30 pm Advancing Breakthrough Medicines through Global Partnership Ji Li, PhD, VP, Business Development and Licensing, Merck
Big pharmaceutical companies are now facing portfolio gaps, caused by patent expiration, pipeline setbacks. Partnership via business development transaction has become an essential part of any successful biopharmaceutical company in our industry, and led to the discovery and development of many great medicines to benefit human health. Dr. Li will use Merck as an example to illustrate the importance of accessing innovation through partnership, how to identify and evaluate partnership opportunities, and how to structure the right kind of
partnership to accelerate the development of external innovation and to maximize the value of the resulting products.
4:30 – 5:00 pm Q&A and Panel Discussion
Symposia B (1:30 – 5:00 pm)
Parallel Session III: Advancing Global Human Health through Collaborative Innovation and Partnership
Session Moderators: Xiaodong Chen, PhD, Lisa Huang, PhD, and Xin Du, PhD 1:30 – 1:50 pm Platforms, Partnerships, and the Power of Convergence
Hui Cai, PhD, VP of PD3, Alliances, PR and Communications, WuXi
AppTec
In a sharing economy transformed by technologies, platform capabilities, and the convergence of disciplines and industries, biopharma innovation is also being significantly redefined and accelerated by similar forces. The presentation provides WuXi’s insights from experience of working with over 2,000 collaborators and partners worldwide through its open-access enabling R&D enabling platform.
1:50 – 2:10 pm Cholangiocarcinoma- Mutational Profiling and Drug Development Milind Javle, MD, Professor of GI Medical Oncology, MD Anderson Cancer Center
Cholangiocarcinoma (cancer of the bile ducts) is growing in incidence. While still considered as rare in the U.S., its annual incidence is approximately 15,000 cases per year. In other parts of the world in including Thailand and China, this rate is much higher. Risk factors include inflammatory bowel disease, obesity, hepatitis and parasitic infections. Most patients are diagnosed at an advanced disease stage and the prognosis is poor. Recent efforts at molecular characterization have revealed that this cancer has a number of actionable genetic mutations, far more than any gastrointestinal cancer. These include mutations in IDH1, FGFR, BRAF and mTOR pathway genes. Ongoing clinical trials indicate promising results targeting these mutations and also reveal success results with immune therapy.
Drug development in this cancer is a priority as per NCI. No anticancer agent has been FDA approved for cholangiocarcinoma in the recent times and a valuable opportunity exists in this cancer type for ‘orphan’ drug designation for any promising therapeutic modality. The potential agents include small molecule RTK inhibitors, immune targeted agents, novel intrahepatic therapeutics and cytotoxic agents with high safety profile. A review of the current science in this disease as well as potential collaborative opportunities will be presented.
2:10 – 2:30 pm Develop a Business Platform for Entering the US Generic Drug Market 打造美国仿制药市场业务平台
John Hu, PhD, Sr. Vice President, Huahai Pharmaceutical US Inc.
Huahai Pharmaceutical is the leader among the first Chinese companies that launch the generic products in the US. This presentation will briefly discuss the challenges and opportunities facing the Chinese companies in the US, and the company’s strategy to grow business in the competitive US generic drug market place.
美国仿制药行业未来将继续呈高速、稳定的发展。但可仿制的产品将减少、产品短缺趋势增 加，新化合物专利药批准率低（专利悬崖）。 大宗仿制药面临重新洗牌，主流企业转向特 色仿制药业务。 过去两年 cGMP 仍然是仿制药企业要面临的严峻课题。 印度企业由于此前 不合规引起的后果，预计药厂以后通过 FDA-cGMP 审计更难，同时 GDUFA 监管要求使得 仿制药研发生产成本大大提高。在后专利悬崖时代，为了确保在后专利悬崖时代的有效的持 续增长，企业和药品流通领域追求规模效应-同业兼并和跨行业联盟成为主流。 可以预见仿 制药制作厂商在市场上围绕着产品种类、价格优惠、质量稳定、供货可靠等的全方面的竞争 将会上一个更深、更高的层次。仿制药市场的竞争是行业资源的竞争、企业整体实力的竞 争。 作为国内第一批通过美国 FDA 制剂生产 cGMP 现场审计及获得仿制药（ANDA）批准 文号的厂家，华海目前在美国已有 20 多个通用名药在美国被 FDA 批准并在在市场销售， 2012 年华海美国收购美国寿科销售公司后，不少品种现已位居美国市场份额首位。
我们将开放华海经过十年打造的美国仿制药研发，注册申报，cGMP 审计及市场销售的业务 平台， 利用中国在传统原料药国际市场上的优势， 与中国优势原料药及制剂企业进行战略 合作，共同打造进入美国市场的企业群体，联手开发 ANDA 及创新制剂产品，推动中国药 企向国际高标准升级转型及产业价值链的延伸。
2:30 – 2:50 pm Synthetic Biology – A Frontier of Biotechnology and Its Relevance to the Biomedical World
Jeffrey Hung, PhD, MBA, Vice President, GenScript
Synthetic biology is an emerging biotechnology discipline that harnesses the power of gene synthesis technology on a wide range of applications. Applications include specialty chemicals, enzymes, synthetic genes and other DNA parts as well as pharmaceuticals, diagnostics, agricultural seeds, vaccines, biofuels, and chassis microorganisms. The talk will focus on the recently developed technologies that empower the efficient assembly of genes in vitro and in vivo for bio-molecule expression and production. Furthermore, he will highlight codon optimization and RBS calculator technologies that one can use to enhance the protein expression of difficult-to- express proteins in E.coli and mammalian cells. Finally he will discuss a successful case study of recombinant antibody development using gene synthesis technologies.
2:50 – 3:10 pm Q&A and Panel Discussion
Session Moderators: Charles Bao, PhD, Xiaoli Wang, PhD, and John Tan, PhD
1:30 – 1:50 pm Drug Discovery in China
Yusheng Wu, PhD, CEO, Tetranov Biopharm
The presentation will discuss the current drug discovery environment, strategies and examples in China. It will also introduce a PE fund for new drug development, IPO, internet medicals/devices, and precision medicines.
1:50 – 2:10 pm CHENPON – Requirement – Innovation
Dizheng Du, EMBA, CEO, Shanghai Chenpon Pharmaceutical
Shanghai Chenpon Pharmaceutical Technology Co., Ltd. is a dynamic and rapid growing pharmaceutical company in China. It is an end-to-end pharmaceutical company with R&D, API/drug product manufacturing /commercialization, and marketing/sales with commercial products in China. Innovation and effective
partnership has been the key to the success of Shanghai Chenpon Pharmaceutical. The presentation will introduce Chenpon’s innovation capability and the business model for effective collaborations. The presentation will also focus on Chenpon new global strategy on the development of inhalation and injectable products for global market. Additionally the speaker will present Chenpon International Incubator in Nantong Site. This international Incubator is open to the scientists and entrepreneurs, and Chenpon is committed to work with scientists and entrepreneurs together to turn the ideas into products on this platform.
2:10 – 2:30 pm Pharmaceutical Industry in China, Challenges and Opportunities Eric Rong, President, Klus Pharma Inc., subsidiary of Kelun Pharmaceuticals
Pharmaceutical industry had developed in China with very high speed in the past 20 years. New drug development for both NDA and ANDA becomes the most important effort for all leading pharmaceutical companies. To build up their R&D teams and for more NDA and ANDA submissions, these leading companies have increased their investment in Research and Development each year.
However, compare to US pharmaceutical industry, pharmaceutical industry in China still fall behind many years. As one of the greatest country, we have the talent and capability to become the leading force. We need not only to invest more money, but also learn from other countries ahead of us. International Partnership and having talented people join our team will greatly help the effort to have Chinese Pharmaceutical Industry become one of the most important industry in the world.
We do realize the challenges we face. But challenges also bring opportunities for us.
2:30 – 2:50 pm May the Odds Be Forever in Your Favor – Surveying and Thriving in the Drug Development World
Haishan Xiong, PhD, MBA, Chief Business Officer of KBP Biosciences
New drug development is a tough business, to say the least. New drug development by a tiny biotech is near suicide. Yet, thousands of brilliant minds in this industry devote their lives to this. And that spirit has been driving KBP BioSciences from nothing to owning an enviable pipeline in its short 10-year history. We focus on 3 key therapeutic areas: organ protection, anti-infective, and inflammation, each of which has a clinical stage compounds being tested in the US. Through this presentation Dr. Xiong will discuss KBP’s research strategy, the compounds as well as KBP’s plans for the future.
2:50 – 3:10 pm Q&A and Panel Discussion
Session Moderators: Jerry Liu, PhD, Chenchao Gao, and Ling Kang, PhD
3:30 – 3:50 pm China Rising – Industrial Perspectives of Current Changes in Chinese Pharmaceutical World
Xin Jiang, PhD, Head of Global Business Development, CoSci Med-Tech Co., Ltd.
1.3 billion Chinese citizens are getting richer and richer, and they require living a happier and healthier life. Medicinal products, especially oral solid medicines are the major foundation in citizens daily lives to support their health kill their diseases and enhance their quality of daily life. China has developed so well in the past decades in economy and many other aspects, however pharmaceutical industry was lagged. Current changes in regulatory and policies from the Central Government of China and CFDA are meaningful to guaranteeing the quality, accessibility, efficacy and safety of medicines and improving the regulatory processes. These changes would lead to golden chances for the industry and personal carriers in China.
3:50 – 4:10 pm China Pharmaceutical Industry Outlook & Exploration of Industrial Acceleration
George Li, PhD, General Manager, Bridge Biomed (武汉光谷百桥国际 生 物科技有限公司)
The presentation will elaborate the China pharmaceutical industry outlook and exploration of industrial acceleration.
China biopharmaceutical industry has been ranked as no. 3 worldwide in term of the size and has experienced a double-digit growth rate in the past ten years. From 2011 to 2015, the average growth of the global pharmaceutical market dropped to low range of 3.5~4.0%. Rapid growth in drug demand in developing countries including China. After a close look at the market rapid expansion, the Market Drivers, plentiful R&D Resources and favorable policies, it was clear that all of those contribute to opportunities of Chinese Bio-pharmaceutical Industry.
In this presentation, the status, problems and new trends on Chinese Pharmaceutical Industry and life science Park in China are summarized. Established with the aim of providing a bridge between international biotech companies and the vast Chinese market, Bridgebio International Corporation is a leading life science incubator in China and can provide fast access to the rapidly growing Chinese market and one stop professional services to both domestic and international clients
4:10 – 4:30 pm Invest for Pharmaceutical Innovation: News from HengRui Pharma Research
Weimin Tang, PhD, Executive Director, HengRui Medicine
Innovation is the life line for pharma industry. Although HengRui was well known as the Pharma in China with strong generic drug product line, innovation has always been in the company blood. The presentation will introduce HengRui’s current innovation capability and capacity, its continuing effort in building and strengthening its innovation engine and overall strategy to be a China-based global pharmaceutical company.
4:30 – 5:00 pm Q&A and Panel Discussion
Speakers and Panelists
Terry Adams
Vice President, Marketing, Shimadzu Corporation
Terry Adams is about to complete his 27th year with Shimadzu. During that time he held the positions of Field Technical Support, Sales, Sales Manager, Marketing Manager, Business Unit Manager, and currently Vice President of Marketing.
Terry obtained his BS in Chemistry from University of Maryland Eastern Shore while working on a NASA grant studying aflatoxins and then a NIH Marine Pharmacognosy project studying algal toxins. He worked as a medical laboratory technician at Rockingham Memorial Hospital, then at Johns Hopkins School of Public Health – Pulmonary Physiology with focus on asthma, ozone and biochemistry of the lung. It was from that position using Shimadzu equipment that was ‘plucked’ into his decades’ employment with Shimadzu.
Hui Cai, PhD
VP of PD3, Alliances, PR and Communications, WuXi AppTec
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of PD3 (Product Definition, Design and Development), Corporate Alliances, and Head of PR and Corporate Communications. Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
Wei (William) Cao, PhD
CEO, Cellular Biomedicine Group, Inc.
Dr. Cao is the CEO of Cellular Biomedicine Group Inc (CBMG). CBMG is currently the only Nasdaq listed China originated company focusing on the development of (stem) cell medicine technology. Dr. Cao has 30 years professional experience in scientific research, products development and startups. William served as Technical Manager for Bayer Diagnostics Asia Pacific region, President of Wuxi New District Hospital, and China General Manager of Affymetrix, a world leader in genetic analysis industry. Dr. Cao is invited as Guest Scientist by Department of Histology and Embryology of Fudan University Medical College, appointed as member of the Committee of International Cellular Medicine Society and American Association of Blood Banks (AABB) for the Development of the Standards for the practice of Cell-Based Medicine, a member of Expert Committee of Regenerative Medicine and Cell Therapy Clinical Application of Chinese Medical Doctor Association (CMDA), and Deputy Director of the Biological Therapy Committee of Chinese Research Hospital Association. Dr. Cao received prestigious White Magnolia Award from Shanghai City for his contribution to international collaboration and economic development of the city. William earned a Bachelor’s degree in Medicine from Fudan University Medical College, Shanghai, China and a PhD degree in Pharmacology from Medical College of Virginia. Dr. Cao had conducted extensive research in immune-pharmacology field at Harvard Medical School and Stanford University Medical Center.
Dizheng Du, EMBA
CEO, Shanghai Chenpon Pharmaceutical Technology Co., Ltd.
Mr. Dizheng Du is the founder and CEO of Shanghai Chenpon Pharmaceutical Co., Ltd. He founded in 2002. Mr. Du has extensive R&D, sales and marketing experience in pharmaceutical industry. His critical insight on drug markets, management skills on business model, creativity and innovation have enabled him to make remarkable achievements repeatedly, which has been reflected by the successes of Shanghai Chenpon Pharmaceutical Co., Ltd.
Shanghai Chenpon is an end-to-end pharmaceutical company with R&D, API/drug product manufacturing /commercialization, and marketing/sales. The company has registered dozens of drug products in CFDA successfully in China, and eight products have been launched with great market successes. Currently the company has focused on the development of oral, injectable and inhalation drugs. In addition to Chinese market, Mr. Du has led the company to develop quite a few drug products for global markets. The company’s first ANDA for an injectable product for US market will be submitted to FDA in early 2016.
Mr. Dizheng Du graduated from West China University of Medical Sciences, and then finished his EMBA program in China Europe International Business School.
Paul Greengard, PhD
Vincent Astor Professor, Rockefeller University 2000 Nobel Prize in Physiology or Medicine
Dr. Paul Greengard is the Vincent Astor Professor of Molecular and Cellular Neuroscience at The Rockefeller University and Director of The Fisher Center for Alzheimer’s Research. Greengard received his Ph.D. from Johns Hopkins in 1953 and then did postdoctoral work at the University of London, Cambridge University and the National Institute of Medical Research in England. He returned to the United States in 1959 as Director of the Department of Biochemistry at Geigy (now Novartis) Research Laboratories, leaving in 1967 to return to academia. From 1968 to 1983, Greengard served as Professor of Pharmacology and Psychiatry at Yale University, at which time he moved to his current position at The Rockefeller University.
Greengard’s achievements have earned him many distinguished awards including the Metropolitan Life Foundation Award for Medical Research, the Ralph W. Gerard Prize in Neuroscience from the Society for Neuroscience and The National Academy of Sciences Award in the Neurosciences. In 2000, Greengard was awarded the Nobel Prize in Physiology or Medicine for his discoveries concerning signal transduction in the nervous system. In 2010 he received the Karolinska Institutet’s Bicentennial Gold Medal. He is a member of the National Academy of Sciences and of the National Academy of Medicine.
John Hu, PhD
Sr. Vice President, Huahai Pharmaceutical US Inc.
Dr. John Hu is Senior Vice President of Huahai US Inc. He is currently working with Huahai Pharmaceutical management team to develop its US and international generic drug strategy and business partnership. Prior to joining Huhai, Dr. Hu was the head of USP-China and responsible for the establishment and growth of USP’s R&D Laboratory and business in China. Dr. Hu also held a number of positions in pharmaceutical R&D and management at multinational companies including Roche, Bayer and Novartis. His earlier career includes drug analysis, formulation development, discovery support, R&D outsourcing and project management. Dr. Hu is a board member and past president of Sino American Pharmaceutical Association (SAPA). He has served at the Advisory Board of Drug Information Association-China (DIA-China); Global Advisory Committee for American Quality Association (ASQ), and Editorial Board for Chinese Pharmaceutical Journal. He is a thesis professor for IPEM program at Peking University and a guest professor at Shanghai Jiaotong University.
Lequn Lee Huang, PhD
Chairman, Shanghai Pharma Sinobiopharma Co. 中国上药集团东英药业
黄乐群博士 Dr. Lequn Lee Huang
• 1977 年 考入南京大学化学系，成为恢复高考后第一批大学生
• 1982 年 被美国依阿华州大学化学系录取，成为改革开放后中国第一批公派出国研究生
• 1991 年 被跨国公司拜耳医药美国研究中心聘为药物研究技术中心主任、任高级研究员
• 2005 年回国，任南京大学医学院副院长（任期三年）兼药物化学研究所所长、教授
• 2008 年 9 月 其创办的 Sinobiopharma（东英药业）在纽约上市，任东英药业董事长
• 2012 年 东英药业凭借其创新型生物制药科技被评选为“清科－中国最具投资价值企业 50
强”第二名
• 2013 年经资本重组后现任上海医药集团东英药业董事长，turn into“海归”科学企业家
• Published over 30 scientific papers in professional journals
Rachel W. Humphrey, MD
VP, Immuno-Oncology, Eli Lilly and Company
Dr. Humphrey currently serves as VP, Head of Immuno-Oncology (IO) at Lilly & Company. She is also a member of the Board of Directors of CytomX Therapeutics. Her prior roles include: VP, Head of Immuno-Oncology at AstraZeneca, Chief Medical Officer at Mirati Therapeutics and VP, Immuno-Oncology at Bristol Myers Squibb. Over the course of her career, she has headed up the strategy and registrational development of multiple anti-cancer agents, including AstraZeneca’s PD-L1 inihibitor, tremelimumab and their combination. She also supervised all phases of development of two important anti-cancer therapies: ipilimumab (Yervoy) and sorafenib (Nexavar). Dr. Humphrey studied Medical Oncology at the US National Cancer Institute and Internal Medicine at the Johns Hopkins Hospital. She received her degree in Medicine at Case Western Reserve University and in Biochemistry at Harvard University. Outside of work, Dr. Humphrey is a current and founding member of the CHECKPOINTs, a blues band made up of Immuno-Oncology scientists and physicians who play to enthusiastic reception at the House of Blues in Chicago every year during the ASCO annual meeting.
Jeffrey Hung, PhD, MBA
VP, GenScript
Jeffrey Hung, PhD, is the Vice President of GenScript, a leading biology CRO in the world. Dr. Hung, an innovative leader in growing life science and diagnostics companies, is responsible for global strategy planning and implementation for all service lines including gene synthesis, peptide, protein and antibody production, genome editing. Dr. Hung was the Chief Marketing Officer at ATCC before joining GenScript, responsible for the global sales, marketing, technology acquisition and new products launch of the world’s largest bio-repository. Prior to that role, Dr. Hung was instrumental in growing SABiosciences’ sales in 4 consecutive years which led to the eventual acquisition of the company by QIAGEN in 2011. Dr. Hung was the author of multiple patents, per reviewed publications and book chapters. Jeff earned his PhD from Cornell University, MBA from UC Berkeley, and B.S. from Peking University.
Thad Huston
Group CFO, Medical Devices, Johnson & Jonson, Former President, Xian Janssen Pharmaceuticals
Thad Huston is the Group Chief Financial Officer for Medical Devices responsible for all financial aspects of the businesses worldwide. Thad began his career at Johnson & Johnson in 1991 as a Finance co-op and has held positions of increasing responsibility in the Pharmaceuticals, Consumer and Medical Devices businesses. In 1996, Thad joined the International Development Program in Budapest, Hungary. In 1998, he was promoted to Finance Director, Janssen Russia and in 2000 relocated to Janssen Belgium to support R&D and international Business Development. In 2001, Thad was promoted to Regional Controller, Asia-Pacific Pharmaceuticals and, in 2003 was appointed Marketing Controller for the U.S. Janssen business. In 2004, Thad was promoted to Vice President, Finance for Ortho McNeil Pharmaceuticals and, in 2006 was promoted to Chief Financial and Operations Officer for Pharmaceuticals R&D. From 2010 to 2013, Thad served as the President of Xian-Janssen Pharmaceuticals in China. In this role, he led the integration of the Johnson & Johnson China OTC business across the Pharmaceuticals and Consumer businesses. Thad holds a Bachelor’s degree in Finance from Pennsylvania State University and is a Certified Master Accountant.
Milind Javle, MD
Professor of GI Medical Oncology, MD Anderson Cancer Center
Dr Javle is a Professor of Gastrointestinal (GI) Medical Oncology and Co-Chair of the Biliary Cancer Working Group at MD Anderson Cancer Center in Houston, TX. He has served as a faculty member at MD Anderson Cancer Center.
Dr. Javle received his medical degree at Grant Medical College, University of Bombay, India. He then pursued postgraduate training in Internal Medicine at the State University of New York (SUNY) in Buffalo, NY, followed by a clinical fellowship in medical oncology and as Assistant Professor at Roswell Park Cancer Institute in Buffalo, NY before joining MD Anderson Cancer Center in 2007.
Dr. Javle is the Principal Investigator for a NCI Phase I study of BikDD Nanoparticle for Advanced Cancer of the Pancreas. His research interests include identification of molecular subtypes of pancreatic and biliary cancers and development of novel therapeutics against these cancers. In 2013, Dr. Javle treated 276 new cases of biliary cancers and hopes to contribute his expertise to the P01 which seeks new treatment options for patients with hepatobiliary cancers.
Dr. Javle serves as Vice-Chair of the Clinical Advisory Board for the Cholangiocarcinoma Foundation. The Cholangiocarcinoma Foundation is a non-profit patient advocacy organization.
Xin Jiang, PhD
Head of Global Business Development, CoSci Med-Tech Co., Ltd.
Dr. Jiang is Head of Global Business Development at CoSci Med-Tech Co., Ltd. At CoSci Med- Tech, Dr. Jiang is responsible for global business development, international technology collaboration and project management.
Dr. Jiang holds a PhD at Medical School of Mainz University, where he focused on scientific field of regenerative medicine and bone tissue Engineering. Dr. Jiang also investigated on the pathogenic mechanisms for age-related macular disease at BioInnovations Center of Technology University Dresden. He previously graduated from Peking University with B.S. in life science.
Ji Li, PhD
VP of Business Development and Licensing, Merck Sharp & Dohme
Dr. Ji Li joined Merck in 2013 as VP of Business Development and Licensing, and Head of Late Stage Assessment in Merck Research Laboratories. In this position, Dr. Li is overseeing Merck’s global effort in the assessment of late stage partnering opportunities across all therapeutic areas. Prior to joining Merck, Dr. Li held the position of Executive Director, External R&D at Amgen where he led the company’s search and evaluation function for all product-related business development transactions worldwide. Prior to his business development career, Dr. Li was a discovery scientist at Amgen in the area of bone, inflammatory and metabolic diseases. Dr. Li was a key member of the Amgen team that discovered and validated the critical OPG-RANKL- RANK signaling pathway which has led to the successful development and commercialization of anti-RANKL mAb denosumab for the treatment of osteoporosis, cancer bone metastasis and other bone loss indications.
Dr. Li holds a B.S. from Shanghai Medical University in China and Ph.D. from Mount Sinai School of Medicine in NYC.
Patrice Matchaba, MD
executive VP, Global Head, Cardio-Metabolic Development Franchise, Novartis Pharmaceuticals
ecutive Vice President, Global Head of Development of the Novartis
He joined Novartis South Africa in 2000 as the Country Pharma Organization Chief Scientific Officer. Since moving to Novartis Pharmaceuticals Corporation in the US in 2002, he has held several roles of increasing responsibility in global clinical development, including Global Head Development Franchise, Immunology and Infectious Diseases (IID) and Global Head of Drug Safety and Epidemiology. Recently he was the Global Head of the Integrated Development Functions and Regions (IDFR), which included Global Clinical Operations, Global Clinical Submissions, Integrated Information Sciences, Drug Modelling and Simulation, Development Informatics, Diversity & Inclusion (D&I) and all Medical Country Pharma Organization (CPO) Globally.
Patrice completed his medical training (MD) at the University of Zimbabwe with honors, and is a Gold Medal Fellow of the Obstetrics and Gynecology College of South Africa. In addition, he completed the Harvard Business School’s Program for Management Development in 2001.
Eric Rong
Vice President, Kelun Pharmaceutical Research Institute and President, Klus Pharma Inc., a Subsidiary of Kelun Pharmaceuticals
Mr. Rong graduated from School of Life Sciences, Peking University. He is Vice President, Kelun Pharmaceutical Research Institute and President of Klus Pharma Inc. He has worked at Aventis, Pfizer, Patheon, Novartis and Akorn international pharmaceutical companies with more than 25 years experience of new and generic injectable, ophthalmic, solid dosage, semi-solid dosage product development in the pharmaceutical industry.
Prior to joining Kelun, as the head of Akorn R&D formulation and microbiology team, Mr. Rong led the team to complete over 60 generic injectable and ophthalmic product development and submitted more than 50 injectable and ophthalmic ANDAs to FDA since 2011.
Weimin Tang, PhD
Executive Director, HengRui Medicine
Dr. Weimin Tang is currently Executive Director of Business Development, HengRui Medicine, based in Princeton, NJ. He joined HengRui recently after 5 successful year of Business development at CrownBio. His main interest is asset licensing in and niche project collaboration.
He is trained as Biochemist with combined 17 years of pharmaceutical research experience in Bristol Myer Squibb, Sanofi-Aventis, American Cyanamid (now Pfizer) and Johnson & Johnson.
Dr. Weimin Tang graduated with PhD from Rutgers University, MS from Chinese Academy of Sciences and BS from Zhejiang University.
Yusheng Wu, PhD
CEO of Tetranov Biopharm
Yusheng Wu, Ph.D., founder and CEO of Tetranov Biopharm, a pharmaceutical company focusing on novel drug discovery targets to drug development. Prior to his current position, Dr. Wu worked in CV/CNS Medicinal Chemistry Department of the drug discovery division at Schering-Plough Research Institute for 13 years and made key contributions for many drug discovery projects such as Thrombosis, Obesity, Alzheimer, etc. Obesity and Alzheimer projects were later recommended for the development. Significantly, Alzheimer project is the first in class in clinical trial. Dr. Wu’s extensive resume also includes more than 70 scientific publications in the leading chemistry and medicinal chemistry journals and patents. He is the recipient of 2004 New Jersey Minority Achievement Award, Schering-Plough President Award in 2007 (Alzheimer project). Since 2009, Dr. Wu led his own drug discovery team in Tetranov developed many novel therapeutic drug candidates such as Alk inhibitor for lung cancer, CDK4/CDK6 kinase project for breast cancer, triglyceride lowering project, HBV project, HCV project, Alzheimer diagnostic project, etc. Three of these projects are currently being evaluated in late pre-clinic and will be forwarded to clinic trials soon.
Dr. Wu is a China 1000 Plan expert and member of its evaluation committee. Besides his work in Tetranov, he is a concurrent professor of Zhengzhou University where he supervises Ph.D. and M.S. students. He is also an associate director of Henan Joint Innovation Center of drug discovery and drug safety evaluation. Dr. Wu is a member of the expert committee of Tianjing International Joint Academy of Biomedicine.
Haishan Xiong, PhD, MBA
Chief Business Officer of KBP Biosciences
Haishan is responsible for KBP’s business operations and external alliances. Prior to joining KBP, Haishan was Head of Commercial Strategies of WuXi AppTec, one of the largest global CROs. He was responsible for leading strategic development of new businesses.
Haishan started his pharmaceutical career at Roche Labs and Spectrum Pharma where he spent 12 years learning and leading various aspects of Rx commercialization, including marketing, sales and sales management. He then applied his knowledge at Vitalico LLC, a consumer health company. As co-founder and COO, Haishan led alliance and partnership building with large global companies.
Haishan obtained his PhD in biochemistry from Penn State University, and MBA from the Wharton School. He enjoys hiking, skiing, and watching football games with his family.
Jerome B. Zeldis, MD, PhD
CMO, Celgene Corp; CEO, Celgene Global Health
Jerome B. Zeldis is CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation, Summit, NJ. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and has been at Celgene since February, 1997. He attended Molecular Biophysics and Biochemistry (immunochemistry). Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics and BionorPharma. He has published 122 peer reviewed articles and 24 reviews, book chapters, and editorials.